| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 06/02/2022 | 909.81% | Laidlaw & Co. | → $3.5 | Initiates Coverage On | → Buy |
| 05/25/2022 | 477.03% | Piper Sandler | $30 → $2 | Maintains | Overweight |
| 05/11/2022 | 477.03% | Morgan Stanley | $8.55 → $2 | Maintains | Underweight |
| 05/10/2022 | 2366.82% | Morgan Stanley | $0.57 → $8.55 | Maintains | Underweight |
| 04/12/2022 | 64.45% | Morgan Stanley | $0.53 → $0.57 | Maintains | Underweight |
| 03/04/2022 | 52.91% | Morgan Stanley | $0.5 → $0.53 | Maintains | Underweight |
| 11/16/2021 | 477.03% | HC Wainwright & Co. | $2.5 → $2 | Maintains | Buy |
| 10/21/2021 | 621.29% | HC Wainwright & Co. | $4 → $2.5 | Maintains | Buy |
| 10/14/2021 | 130.81% | Morgan Stanley | → $0.8 | Downgrades | Equal-Weight → Underweight |
| 08/12/2021 | 188.52% | Morgan Stanley | $3 → $1 | Maintains | Equal-Weight |
| 06/07/2021 | 1054.07% | HC Wainwright & Co. | $7 → $4 | Maintains | Buy |
| 03/08/2021 | 1919.62% | HC Wainwright & Co. | $8 → $7 | Maintains | Buy |
| 10/02/2020 | 1342.59% | Stifel | → $5 | Initiates Coverage On | → Buy |
| 08/20/2020 | — | Morgan Stanley | Initiates Coverage On | → Equal-Weight | |
| 06/09/2020 | 2496.65% | HC Wainwright & Co. | $11 → $9 | Maintains | Buy |
| 06/08/2020 | 3073.69% | Piper Sandler | → $11 | Initiates Coverage On | → Overweight |
| 05/27/2020 | 7112.93% | Oppenheimer | $23 → $25 | Maintains | Outperform |
| 12/11/2019 | 3073.69% | HC Wainwright & Co. | $9 → $11 | Reiterates | → Buy |
| 10/16/2019 | 2496.65% | Cantor Fitzgerald | → $9 | Assumes | → Overweight |
| 09/26/2018 | 2496.65% | Cantor Fitzgerald | → $9 | Initiates Coverage On | → Overweight |
| 06/27/2018 | 2208.14% | RBC Capital | → $8 | Initiates Coverage On | → Outperform |
| 06/18/2018 | 2496.65% | Oppenheimer | → $9 | Initiates Coverage On | → Outperform |
| 03/19/2018 | 4227.76% | HC Wainwright & Co. | → $15 | Initiates Coverage On | → Buy |
Evofem Biosciences Questions & Answers
The latest price target for Evofem Biosciences (NASDAQ: EVFM) was reported by Laidlaw & Co. on June 2, 2022. The analyst firm set a price target for $3.50 expecting EVFM to rise to within 12 months (a possible 909.81% upside). 11 analyst firms have reported ratings in the last year.
The latest analyst rating for Evofem Biosciences (NASDAQ: EVFM) was provided by Laidlaw & Co., and Evofem Biosciences initiated their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evofem Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evofem Biosciences was filed on June 2, 2022 so you should expect the next rating to be made available sometime around June 2, 2023.
While ratings are subjective and will change, the latest Evofem Biosciences (EVFM) rating was a initiated with a price target of $0.00 to $3.50. The current price Evofem Biosciences (EVFM) is trading at is $0.35, which is within the analyst's predicted range.